The clotting disorder hemophilia is also being studied with this virus-based gene therapy, as AAVs are used to correct defects in the clotting proteins factor VIII (hemophilia A) and factor IX (hemophilia B) [4]. The gene discussed is F9; the disease is hemophilia A.